%0 Journal Article
%T Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
%A Fengjun Cao
%A Guoxing Wan
%A Xuanbin Wang
%A Xue Sun
%J Journal of Cancer
%D 2019
%I Ivyspring International Publisher
%R 10.7150/jca.29461
%X Recombinant humanized monoclonal antibody bevacizumab binding and inactivating VEGF-A has recently been a particularly attractive focus of research in anti-angiogenic treatment strategy for breast cancer especially the HER-2 negative subtype [1]. Three recently published phase III randomized controlled trials-ARTemis [2], GBG 44- GeparQuinto [3] and SWOG S0800 trial [4]-have showed that adding bevacizumab to neoadjuvant chemotherapy (NAC) increased the pathological complete response (pCR) but did not favor the survival of HER-2 negative non-metastatic breast cancer (NMBC), while NSABP B-40 trial [5] contradicted the findings by demonstrating an improved survival particularly disease-free survival (DFS). To settle the disputes, we therefore performed a meta-analysis to evaluate the survival benefit and risk of this treatment strategy.
%U http://www.jcancer.org/v10p0416.htm